Academic Journal
View in EDS
PDF Full Text

Salivary caffeine in Parkinson’s disease

Bibliographic Details
Title: Salivary caffeine in Parkinson’s disease
Authors: Giorgio Leodori, Maria Ilenia De Bartolo, Daniele Belvisi, Alessia Ciogli, Andrea Fabbrini, Matteo Costanzo, Simone Manetto, Antonella Conte, Claudio Villani, Giovanni Fabbrini, Alfredo Berardelli
Source: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Publisher Information: Nature Portfolio, 2021.
Publication Year: 2021
Collection: LCC:Medicine
LCC:Science
Subject Terms: Medicine, Science
More Details: Abstract We aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson’s disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-2322
Relation: https://doaj.org/toc/2045-2322
DOI: 10.1038/s41598-021-89168-6
Access URL: https://doaj.org/article/a18969ffd7364c09aa30c41879aa4f47
Accession Number: edsdoj.18969ffd7364c09aa30c41879aa4f47
Database: Directory of Open Access Journals
FullText Links:
  – Type: pdflink
    Url: https://content.ebscohost.com/cds/retrieve?content=AQICAHjPtM4BHU3ZchRwgzYmadcigk49r9CVlbU7V5F6lgH7WwHsd5_pmt9fMu4BqpWQciweAAAA4jCB3wYJKoZIhvcNAQcGoIHRMIHOAgEAMIHIBgkqhkiG9w0BBwEwHgYJYIZIAWUDBAEuMBEEDG6he6m32fLEc9SbmAIBEICBmvfz4TNfpsZnQlGRBDSps6IIvXMwv0hSrXfZkcpIx-U6PZnxAcxAok8quf2ucVg3i2pIO6ZDPVVFB9f4SOrk2y4pcNd0Goks0cz4Zt8XLaxwldnumkWBeorydOM7gI0q0nKQBt7vlgbkCuyMOU6bTbYB8wOmrOao8qP80iTZTY5dNnoytSqlxrvcduGI4RJESqVQ2xHSwxjP2xc=
Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=20452322&ISBN=&volume=11&issue=1&date=20210501&spage=1&pages=1-9&title=Scientific Reports&atitle=Salivary%20caffeine%20in%20Parkinson%E2%80%99s%20disease&aulast=Giorgio%20Leodori&id=DOI:10.1038/s41598-021-89168-6
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/a18969ffd7364c09aa30c41879aa4f47
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.18969ffd7364c09aa30c41879aa4f47
RelevancyScore: 949
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 948.723937988281
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Salivary caffeine in Parkinson’s disease
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Giorgio+Leodori%22">Giorgio Leodori</searchLink><br /><searchLink fieldCode="AR" term="%22Maria+Ilenia+De+Bartolo%22">Maria Ilenia De Bartolo</searchLink><br /><searchLink fieldCode="AR" term="%22Daniele+Belvisi%22">Daniele Belvisi</searchLink><br /><searchLink fieldCode="AR" term="%22Alessia+Ciogli%22">Alessia Ciogli</searchLink><br /><searchLink fieldCode="AR" term="%22Andrea+Fabbrini%22">Andrea Fabbrini</searchLink><br /><searchLink fieldCode="AR" term="%22Matteo+Costanzo%22">Matteo Costanzo</searchLink><br /><searchLink fieldCode="AR" term="%22Simone+Manetto%22">Simone Manetto</searchLink><br /><searchLink fieldCode="AR" term="%22Antonella+Conte%22">Antonella Conte</searchLink><br /><searchLink fieldCode="AR" term="%22Claudio+Villani%22">Claudio Villani</searchLink><br /><searchLink fieldCode="AR" term="%22Giovanni+Fabbrini%22">Giovanni Fabbrini</searchLink><br /><searchLink fieldCode="AR" term="%22Alfredo+Berardelli%22">Alfredo Berardelli</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Nature Portfolio, 2021.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2021
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Medicine<br />LCC:Science
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Science%22">Science</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Abstract We aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson’s disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2045-2322
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://doaj.org/toc/2045-2322
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1038/s41598-021-89168-6
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/a18969ffd7364c09aa30c41879aa4f47" linkWindow="_blank">https://doaj.org/article/a18969ffd7364c09aa30c41879aa4f47</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.18969ffd7364c09aa30c41879aa4f47
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.18969ffd7364c09aa30c41879aa4f47
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41598-021-89168-6
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 1
    Subjects:
      – SubjectFull: Medicine
        Type: general
      – SubjectFull: Science
        Type: general
    Titles:
      – TitleFull: Salivary caffeine in Parkinson’s disease
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Giorgio Leodori
      – PersonEntity:
          Name:
            NameFull: Maria Ilenia De Bartolo
      – PersonEntity:
          Name:
            NameFull: Daniele Belvisi
      – PersonEntity:
          Name:
            NameFull: Alessia Ciogli
      – PersonEntity:
          Name:
            NameFull: Andrea Fabbrini
      – PersonEntity:
          Name:
            NameFull: Matteo Costanzo
      – PersonEntity:
          Name:
            NameFull: Simone Manetto
      – PersonEntity:
          Name:
            NameFull: Antonella Conte
      – PersonEntity:
          Name:
            NameFull: Claudio Villani
      – PersonEntity:
          Name:
            NameFull: Giovanni Fabbrini
      – PersonEntity:
          Name:
            NameFull: Alfredo Berardelli
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 20452322
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Scientific Reports
              Type: main
ResultId 1